EP Patent

EP0825858B1 — Time-dependant release capsules containing omega-3 polyunsaturated acids for the treatment of inflammatory bowel disease

Assigned to Tillotts Pharma AG · Expires 2005-05-04 · 21y expired

What this patent protects

Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases…

USPTO Abstract

Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).

Drugs covered by this patent

Patent Metadata

Patent number
EP0825858B1
Jurisdiction
EP
Classification
—
Expires
2005-05-04
Drug substance claim
No
Drug product claim
No
Assignee
Tillotts Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.